A Chat With Immuno-oncology Trailblazer Exec Dan Chen

In the last decade, anti-PD-1/L1 checkpoint inhibitors have been revolutionary in oncology, but while the impact has been dramatic, many patients still do not respond. Dan Chen, M.D., Ph.D., former global head of the cancer immunotherapy franchise at oncology leader Roche/Genentech, talks to Scrip and Pink Sheet journalist Emily Hayes about the cancer immunity cycle, lessons learned from trials of combinations of drugs and more. Recorded onsite at the ASCO-SITC Clinical Immuno-Oncology Symposium in San Francisco on March 1, 2019.